Rosetta Grants Prometheus Rights to Sell Suite of microRNA Diagnostics in US | GenomeWeb

This story has been updated to include comments from Rosetta's president and CEO.

Rosetta Genomics
this week announced that it has granted the right to market and sell its three microRNA-based diagnostics in the US to drug and diagnostic firm Prometheus Laboratories.

The deal is the latest move by Rosetta to find commercialization partners for its existing products as it shifts its focus onto non-invasive tests designed to screen for, rather than diagnose, disease.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.